Breast Cancer Clinical Trials in Rochester, New York

9 studies are recruiting for breast cancer in Rochester, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Rochester Medical, Rochester, New York

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

2. A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

   The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) an…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Wilmot Cancer Institute, Rochester, New York

   Locations

   50 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05307705 on ClinicalTrials.gov

3. Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

   Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of we…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Locations

   4 in total

   Run by

   Ruth O'Regan

   See if you can join NCT04886531 on ClinicalTrials.gov

4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Pluta Cancer Center, Rochester, New York

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

5. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Rochester - Wilmot Cancer Institute, Rochester, New York

   Locations

   10 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

6. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Rochester Wilmot Cancer Institute, Rochester, New York

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov

7. SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

   Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for surgeons plus patient decision aid vs. usual care (UC), at 7 large health systems across the U.S. to l…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Rochester, Rochester, New York

   Locations

   11 in total

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT06896474 on ClinicalTrials.gov

8. Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

   The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Rochester, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT04965064 on ClinicalTrials.gov

9. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

   The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Rochester - Pluta Cancer Center, Rochester, New York

   Locations

   134 in total

   Run by

   Agendia

   See if you can join NCT03053193 on ClinicalTrials.gov